Use access key #2 to skip to page content.
$0.25 0.02 (8.70%)
9/5/2008 3:54 PM

Critical Therapeutics, Inc. (CRTX)

CAPS Rating:
*****

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

View All Commentary (CRTX)

Recs

1

Avatar jupamc (< 20) Submitted: 6/19/07 3:30 PM : Outperform Start Price: $2.36 CRTX Score: -70.64

Expect major revenue increases starting 2H07 due to increase of effective salesforce from 20 to 240 with Dey partnership and new reformulation of zileuton (ZyFlo CR). May see some earlier rev. uptick due to co-marketing started in Q2. New formulation is a feasible alternative advantage to Singulair, which some people are reporting, produces side effects such as depression, anxiety.

Report this Post Replies: 0 | Reply

Featured Broker Partners